Abstract
A two component system, consisting of a fusion protein and an appropriate prodrug, suited to perform selective tumor therapy in vivo, is presented. The fusion protein, owing to its humanized carcinoembryonic antigen (CEA)-specific variable region, specifically binds to CEA-expressing tumors and has an enzymatic activity comparable to human β-glucuronidase. The prodrug is a nontoxic glucuronide-spacer-derivative of doxorubicin decomposing to doxorubicin by enzymatic deglucuronidation.
In vivo studies in nude mice bearing human CEA-expressing tumor xenografts revealed that 7 d after injection of 20 mg/kg fusion protein, a high specificity ratio (>100:1) was obtained between tumor and plasma. Injection of 250 mg/kg of prodrug at d 7 resulted in tumor therapeutic effects superior to conventional chemotherapy without any detectable toxicity. These superior therapeutic effects that were observed using established human tumor xenografts can be explained by the approx 10-fold higher drug concentrations found in tumors of mice treated with fusion protein and prodrug than in those treated with the maximal tolerable dose of drug alone.
Similar content being viewed by others
References
Ford, J. M. and Hait, W. N. (1990)Pharmacol. Reviews 42, 155.
Senter, P. D., Wallace, P. M., Svensson, H. P., Vrudhula, V. M., Kerr, D. E., Hellström, I., et al. (1993)Bioconjugate Chem. 4, 3.
Sharma, S. K., Bagshawe, K. D., Springer, C. J., Burke, P. J., Rogers, G. T., Boden, J. A., et al. (1991)Disease Markers 9, 225.
Bagshawe, K. D., Sharma, S. K., Springer, C. J., Antoniw, P., Boden, J. A., Rogers, G. T., et al. (1991)Disease Markers 9, 233.
Bosslet, K., Czech, J., Lorenz, P., Sedlacek, H. H., Schuermann, M., and Seemann, G. (1992)B. J. Cancer 65, 234
Jacquesy, J.-C., Gesson, J.-P., Monneret, C., Mondon, M., Renoux, B., Florent, J.-C., et al. Prodrogues glycosylées, leur procédé de préparation et leurs utilisation. Demande de brevet européen, EP 0 511 917 A1.
Bagshawe, K. D., Sharma, S. K., Springer, C. J., Antoniw, P., Rogers, G. T., Burke, P. J., et al. (1991)Antibody, Immunoconjugates and Radiopharmaceuticals 4, 915.
Jain, K. R. (1987)Cancer Res. 47, 3039.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bosslet, K., Czech, J., Seemann, G. et al. Fusion protein mediated prodrug activation (FMPA) in vivo. Cell Biophysics 24, 51–63 (1994). https://doi.org/10.1007/BF02789215
Issue Date:
DOI: https://doi.org/10.1007/BF02789215